新华社布加勒斯特2月27日电近日发表在国际学术期刊《微生物学前沿》上的一项新研究显示，在罗马 尼亚一处数千年历史的冰洞中发现的一种古老细菌对多种现代常用抗生素具有耐药性，表明细菌的耐药 性可以在自然演化中形成。 这种细菌发现于罗马尼亚一处冰洞约5000年前形成的冰层中。罗马尼亚科学院布加勒斯特生物研究所等 机构的研究人员在冰洞中钻取了一根长25米的冰芯，从中分离出多种细菌菌株，并对它们的基因组测序 分析，以研究其耐寒机制以及耐药性相关基因等。 研究人员利用10大类的28种临床常用或储备用抗生素对其中一种名为SC65A.3的嗜冷菌菌株进行测试， 发现它对其中的10种抗生素表现出耐药性，包括利福平、万古霉素和环丙沙星等用于治疗常见感染的药 物。SC65A.3也是第一种被发现对甲氧苄啶、克林霉素、甲硝唑等抗生素具有耐药性的嗜冷菌菌株。 研究还发现，SC65A.3携有百余个与耐药性相关的基因，还能抑制多种多重耐药"超级细菌"的生长，并 具备具有生物技术应用潜力的特殊酶活性。 研究人员认为，能够在寒冷环境存活的菌株可能是抗生素耐药性基因的"天然储库"。针对SC65A.3等古 老微生物的研究展现了抗生素耐药性如何在自然环 ...

研究还发现，SC65A.3携有百余个与耐药性相关的基因，还能抑制多种多重耐药"超级细菌"的生长，并 具备具有生物技术应用潜力的特殊酶活性。 研究人员认为，能够在寒冷环境存活的菌株可能是抗生素耐药性基因的"天然储库"。针对SC65A.3等古 老微生物的研究展现了抗生素耐药性如何在自然环境中演化出来，而这远早于现代抗生素的使用。 新华社布加勒斯特2月27日电（记者张改萍）近日发表在国际学术期刊《微生物学前沿》上的一项新研 究显示，在罗马尼亚一处数千年历史的冰洞中发现的一种古老细菌对多种现代常用抗生素具有耐药性， 表明细菌的耐药性可以在自然演化中形成。 这种细菌发现于罗马尼亚一处冰洞约5000年前形成的冰层中。罗马尼亚科学院布加勒斯特生物研究所等 机构的研究人员在冰洞中钻取了一根长25米的冰芯，从中分离出多种细菌菌株，并对它们的基因组测序 分析，以研究其耐寒机制以及耐药性相关基因等。 研究人员利用10大类的28种临床常用或储备用抗生素对其中一种名为SC65A.3的嗜冷菌菌株进行测试， 发现它对其中的10种抗生素表现出耐药性，包括利福平、万古霉素和环丙沙星等用于治疗常见感染的药 物。SC65A.3也是第一种被发现对甲 ...

Core Insights - The article discusses a recent study published by South China Normal University, highlighting the relationship between environmental exposure and the abundance and transferability of antibiotic resistance genes (ARGs) in the respiratory tract [2][4]. Group 1: Study Findings - Exposure to environmental pollutants is linked to an increase in respiratory antibiotic resistance genes (ARGs) [5]. - The abundance and mobility of antibiotic resistance genes are negatively correlated with lung function [5]. - Enhanced mobility of antibiotic resistance genes is observed in early chronic obstructive pulmonary disease (COPD) [5]. - Environmental pollutant exposure is associated with increased antibiotic-resistant phenotypes in mouse lungs [5]. Group 2: Implications - The study elucidates a pathway through which environmental pollutants contribute to the increase of the respiratory resistance gene pool, indicating the need for action to mitigate the burden of antibiotic resistance by addressing environmental pollution [6].

Core Insights - A new antibiotic, pre-penicillin C lactone, has been discovered during the production process of a commonly used antibiotic, penicillin A, which shows over 100 times higher antibacterial activity against various Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus [1][2] Group 1 - The research was conducted by Monash University in collaboration with the University of Warwick, highlighting the potential of intermediate compounds in antibiotic synthesis [1] - The discovery provides a new model for identifying and testing intermediates in the synthesis pathways of various natural compounds, which may lead to the development of new antibiotics to combat antibiotic resistance [1]

Core Insights - A new antibiotic with strong efficacy against "superbugs" has been unexpectedly discovered during the production process of a commonly used antibiotic [1] - The antibiotic, named pre-penicillin C lactone, was found to have over 100 times the antibacterial activity against various Gram-positive bacteria compared to the original antibiotic, penicillin A [1] Group 1: Research Findings - Researchers from Monash University and the University of Warwick identified the antibiotic during the synthesis of penicillin A, which has been known for 50 years but had not been tested for the antibacterial activity of its intermediates [1] - The newly discovered pre-penicillin C lactone is effective against troublesome bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus [1] Group 2: Implications for Antibiotic Development - This discovery provides a new model for finding novel antibiotics by identifying and testing intermediates in the synthesis pathways of various natural compounds [1] - The research highlights the potential for discovering more effective antibiotics to combat antibiotic resistance, a significant issue in modern medicine [1]

Core Insights - A new antibiotic called pre-vancomycin C lactone has been discovered, showing over 100 times higher antibacterial activity against various Gram-positive bacteria compared to the commonly used antibiotic vancomycin A, including resistant strains like MRSA and VRE [1] - The discovery provides a new model for finding novel antibiotics, potentially aiding in the fight against antibiotic resistance [1] Industry Overview - As of November 10, there are 45,700 existing biopharmaceutical companies in China, with 39% located in South China and 32.8% in East China [2] - The registration of biopharmaceutical companies in 2025 has reached 3,311, surpassing the total for 2024, marking a year-on-year increase of 27.3% [3] - In 2025, new registrations are predominantly from East China, accounting for 45.1%, while South China contributes 29.8% [4]

Core Insights - Researchers have discovered a promising new antibiotic, pre-penicillin C lactone, which is effective against "superbugs" resistant to multiple antibiotics, including methicillin-resistant Staphylococcus aureus (MRSA) [1][2] Group 1: Research Findings - The antibiotic pre-penicillin C lactone was found during the production process of the commonly used antibiotic penicillin A, and it exhibits over 100 times higher antibacterial activity against various Gram-positive bacteria compared to penicillin A [1] - This discovery highlights the potential of identifying and testing intermediates in the synthesis pathways of natural compounds to find new antibiotics that can effectively combat antibiotic resistance [1] Group 2: Academic Collaboration - The research was conducted by Monash University in collaboration with the University of Warwick in the UK, indicating a strong international partnership in addressing antibiotic resistance [1]

Core Insights - The World Health Organization (WHO) warns that antibiotic resistance is a growing global health threat, with a significant increase in resistance to commonly used antibiotics [1][2] Group 1: Antibiotic Resistance Statistics - In 2023, one in six laboratory-confirmed bacterial infections globally showed resistance to antibiotic treatment [1] - From 2018 to 2023, over 40% of monitored pathogen-antibiotic combinations exhibited rising antibiotic resistance, with an annual increase of 5% to 15% [1] - More than 40% of Escherichia coli and over 55% of Klebsiella pneumoniae have developed resistance to third-generation cephalosporins, with rates exceeding 70% in the African region [1] Group 2: Regional Variations in Resistance - The WHO reports that the highest risks of antibiotic resistance are in the Southeast Asia and Eastern Mediterranean regions, where one-third of infections show resistance [2] - In the African region, the proportion of infections exhibiting antibiotic resistance is one in five [2] Group 3: WHO's Call to Action - WHO Director-General Tedros Adhanom Ghebreyesus emphasizes the need for responsible antibiotic use and the importance of ensuring access to quality diagnostics and vaccines [2]

Core Insights - An international team led by scientists from the University of Liverpool has developed a new antibiotic named Novltex, which shows sustained inhibitory effects against various deadly superbugs, marking significant progress in the fight against antibiotic resistance [1][2] - Antibiotic resistance is listed as one of the top ten health threats to humanity, causing nearly 5 million deaths annually, with the WHO highlighting the urgent need for new antibiotics [1] - Novltex targets lipid II, a crucial component of bacterial cell walls that is less prone to mutation, offering durable resistance protection against antibiotic resistance [1][2] Summary by Sections Development and Testing - Novltex was inspired by the existing antibiotics Teixobactin and Clofazimine, avoiding the use of expensive raw materials and allowing for the construction of numerous candidate molecules for optimization [2] - The antibiotic demonstrates sustained antibacterial capabilities, remaining effective at low doses and outperforming existing antibiotics like Vancomycin and Daptomycin, with no toxicity to human cells [2] Significance and Potential - The combination of efficiency, durability, and scalability makes Novltex one of the most promising antibiotic candidates in decades [2] - The synthetic efficiency of Novltex is reported to be 30 times higher than that of natural products, enhancing its potential for mass production [2]

Summary of SoftOx Solutions Investor Update Call Company Overview - **Company**: SoftOx Solutions AS - **Industry**: Pharmaceutical, specifically focusing on inhaled antimicrobial therapies Key Points and Arguments 1. **Technological Potential**: The company believes its technology can significantly change the treatment of lung infections, particularly through the SoftOx Inhalation Solution, which utilizes hypochlorous acid to combat various pathogens [2][10][12] 2. **Clinical Adoption and Commercial Value**: Emphasis on the need for clinical adoption at scale to achieve commercial value and shareholder rewards [3][6] 3. **Proof-of-Concept Study**: The company is initiating its first proof-of-concept study targeting cystic fibrosis patients, which is seen as a critical step in demonstrating the efficacy of their technology [3][12][35] 4. **Market Potential**: The addressable market for cystic fibrosis is estimated at around $600 million, with potential annual turnover of approximately $90 million if the company captures a 15% market share [28][29] 5. **Broader Applications**: The technology may also be applicable to other chronic lung infections, such as non-cystic fibrosis bronchiectasis, which presents a larger market opportunity [15][29][36] 6. **Antibiotic Resistance**: The SoftOx Inhalation Solution is positioned as a solution to the growing problem of antibiotic resistance, with the ability to target dormant bacteria and biofilms [11][12][18] 7. **Clinical Trial Design**: The upcoming trial will involve higher dosages and a more homogeneous patient population, which is expected to yield robust data on bacterial load reduction [19][20][21] 8. **Funding and Financial Strategy**: The company has established an equity placement facility to raise up to NOK 50 million, with the option to extend to NOK 80 million, providing financial security and strategic flexibility [43][44] Additional Important Information 1. **Regulatory Engagement**: The company has been in contact with EMA and FDA for scientific advice regarding clinical trials and orphan drug designation [39][40] 2. **Partnership Strategy**: SoftOx is open to partnerships for commercialization but will focus on generating proof-of-concept data first before engaging in formal discussions [49][50] 3. **Equity and Dilution Concerns**: The company acknowledges the need for equity issuance to fund operations, which may lead to dilution, but emphasizes the importance of this funding for advancing their clinical trials [51][52] 4. **Long-term Vision**: The management team is optimistic about the future, believing that successful clinical data will attract interest from global pharmaceutical companies for partnerships by 2027 [36][55] This summary encapsulates the key insights from the investor update call, highlighting the company's strategic direction, market potential, and the importance of upcoming clinical trials in validating their technology.